We find that ACAT inhibition drives metabolic re-modelling, resulting in enhanced expansion and functionality of human CD8+ T cells directed against HBV and HCC, sampled directly from the site of disease. The gene discussed is CD8A; the disease is hepatocellular carcinoma.